| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H18F3NO5 |
| Molecular Weight | 349.3023 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC[C@H]1CN(C(=O)O1)C2=CC=C(OCC[C@@H](O)C(F)(F)F)C=C2
InChI
InChIKey=IALVDLPLCLFBCF-CHWSQXEVSA-N
InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1
| Molecular Formula | C15H18F3NO5 |
| Molecular Weight | 349.3023 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Befloxatone (MD-370,503) is a reversible inhibitor of monoamine oxidase A that was developed by Synthelabo for the treatment of depression, social phobias, and panic disorders. This drug participated in phase III clinical trials in France for depression. In addition participated in phase II for smoking cessation, anxiety disorders. Befloxatone has a good safety profile, lacking sedative, convulsant, anticholinergic and cardiovascular effects. However, all studies were discontinued.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
To assess the effects of single oral doses of befloxatone (5, 10, and 20 mg) on psychomotor performance and memory, a randomized, double-blind, five-way, crossover study with both placebo and amitriptyline (50 mg) was carried out in 15 healthy male volunteers.
Route of Administration:
Oral
